

Brief report

Does major depressive disorder with somatic delusions constitute a distinct subtype of major depressive disorder with psychotic features?

Taafoi S. Kamara^a, Ellen M. Whyte^a, Benoit H. Mulsant^{a,b,c,*},
Catherine Peasley-Miklus^{d,e}, Anthony J. Rothschild^{f,g}, Alastair J. Flint^{c,h,i,j},
Moonseong Heo^{d,e}, Eros Papademetriou^{d,e}, Erin R. Mathis^a, Barnett S. Meyers^{d,e}
for the STOP-PD Study Group

^a Western Psychiatric Institute and Clinic and Department of Psychiatry, University of Pittsburgh School of Medicine, United States

^b Center for Addiction and Mental Health, Toronto, Canada

^c Department of Psychiatry, University of Toronto, Canada

^d Department of Psychiatry, Weill Medical College of Cornell University, United States

^e New York Presbyterian Hospital-Westchester, United States

^f Department of Psychiatry, University of Massachusetts Medical School, United States

^g University of Massachusetts Memorial HealthCare, United States

^h University Health Network, Toronto, Canada

ⁱ The Geriatric Program and Research Institute, Toronto Rehabilitation Institute, Toronto, Canada

^j The Toronto General Research Institute, Toronto, Canada

Received 10 July 2006; received in revised form 20 February 2008; accepted 22 April 2008

Available online 4 June 2008

Abstract

Background: Among patients with major depression with psychotic features, little is known about the extent to which those with and without somatic delusions differ.

Methods: The first 183 participants in the STOP-PD study were divided into two groups based on the presence or absence of somatic delusions and were compared on multiple demographic and clinical characteristics.

Results: In the multivariate analysis, those with somatic delusions reported more somatic symptoms, rated their health as worse, and were less likely to have persecutory delusions.

Conclusions: Based on the methods we used, we could not detect meaningful differences between subjects with and without somatic delusions. This suggests that the presence of irrational somatic ideation does not define a distinct clinical subgroup among patients with psychotic depression. This finding needs to be replicated.

© 2008 Elsevier B.V. All rights reserved.

Keywords: Depression; Psychosis; Somatization; Psychotic depression; Delusions; Subtype

1. Introduction

Major depressive disorder with psychotic features (MD-Psy) constitutes a significant health problem. Also called delusional depression, MD-Psy is present in up to

* Corresponding author. Geriatric Mental Health Program, Center for Addiction and Mental Health, 1001 Queen Street West, Toronto, Ontario, Canada M6J 1H4. Tel.: +1 416 535 8501x3656; fax: +1 416 583 1275.

E-mail address: benoit_mulsant@camh.net (B.H. Mulsant).

25% of younger patients and 45% of older patients in psychiatric hospitals for the treatment of major depression (Coryell et al., 1984; Meyers and Greenberg, 1986).

Clinical and biological evidence suggests that MD-Psy with somatic delusions may represent a specific subtype of MD-Psy. Specifically, patients with MD-Psy with somatic delusions are more likely to be women older (Meyers, 1992) than those with other delusions. They may also have a higher rate of suicide (Schneider et al., 2001) and greater REM activity during sleep (Kupfer, 1976). The presence of somatic delusions may also influence health care seeking behaviors and quality of life. Depressed patients with somatic preoccupations use more medical services than depressed patients without these preoccupations (Barsky et al., 2005) and the presence of somatization predicts poor health-related quality of life among older primary care patients (Sheehan et al., 2005).

Thus, we conducted an analysis to determine whether MD-Psy patients with and without somatic delusions present with differing clinical features. We compared baseline demographic and clinical characteristics of participants with and without somatic delusions among the first 183 participants in STOP-PD (Study of Pharmacotherapy of Psychotic Depression), a randomized controlled trial. We hypothesized that participants with somatic delusions would differ from those without somatic delusions: they would be older, more likely to be female, have a higher objective burden of physical illness, lower self-rated health, poorer health-related quality of life, a higher degree of non-delusional somatic complaints, and higher utilization of health care services.

2. Methods

STOP-PD is an NIMH-sponsored trial conducted at Cornell University, the University of Massachusetts, the University of Pittsburgh, and the University of Toronto. Participants were enrolled based on systematic screening of inpatients and on solicitation of outpatient referrals in these academic centers. Inclusion criteria included: age 18 and older, ability to speak English fluently, a Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV; APA, 1994) diagnosis of MD-Psy based on the Structured Clinical Interview for DSM-IV (SCID-patient version; Spitzer et al., 1995), a score of 21 or higher on the 17-item version of the Hamilton Depression Rating Scale (HDRS-17; Hamilton, 1960), the presence of one or more delusions as indicated by a score of 3 or greater (delusion definitely present) on the delusion item of the Schedule for Affective Disorders and Schizophrenia (SADS; Spitzer and Endicott, 1979). We also required a score of 2 or higher on one or more of

the two conviction items that assess the extent to which reality testing about a possible delusional idea is lost (i.e., subjective feeling of certainty; failure of accommodation to confrontation with evidence contradicting the belief) of the Delusional Assessment Scale (DAS; Meyers et al., 2006). This criterion assures that potentially irrational ideas were held persistently. We excluded patients with current or past DSM-IV diagnosis of bipolar disorder or schizophrenia; current body dysmorphic disorder, obsessive compulsive disorder, or brief psychotic disorder; substance abuse or dependence, including alcohol, within the last three months; Alzheimer dementia, vascular dementia or history of ongoing significant cognitive impairment (from informant report) prior to the index episode; unstable medical illness; medical conditions (such as hypothyroidism), metabolic abnormalities (such as folate or B12 deficiency), or medication (such as carbidopa) that might contribute to psychopathology, confound response to pharmacotherapy, or render patients unable to tolerate or complete the study; inability to tolerate the study medications (sertraline or olanzapine) or having failed to respond to olanzapine 15 mg/day or greater for at least 4 weeks during the index episode; being pregnant or planning to become pregnant; or being sufficiently ill to require immediate open pharmacotherapy or ECT (e.g., due to imminent risk or suicide or refusal to eat). Recruitment was stratified by age on a 1:1 basis to allow for comparisons between younger (<60 years) and older adults. Written informed consent was obtained from all participants (or substitute decision makers, when applicable) using procedures approved by local Institutional Review Boards prior to the initiation of any research assessments.

Upon enrollment, in addition to the SCID, HDRS-17, SADS, and DAS, each participant was administered a battery of clinical instruments at baseline, including the 18-item Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, 1962), Scale for Assessment for Positive Symptoms (hallucinations and delusion items only; SAPS; Andreasen, 1984), Mini-Mental State Examination (MMSE; Folstein et al., 1975), Cumulative Illness Rating Scale for Geriatrics (modified to exclude the psychiatric subscale; CIRS-G; Miller, 1992), 36-item short form of the Medical Outcome Study (SF-36; Stewart et al., 1988) with the Self-Rated Health (SRH) item, physical component scale (PCS) and mental component scale (MCS), Utvalg for Klinisk Undersøgelse (UKU; Lingjaerde et al., 1987) which assesses somatic complaints, and Cornell Health Services Index (CSI; Sirey et al., 2005) which assesses use of health services over the past 3 months. Inter-rater reliability was established for the HDRS-17, BPRS and

DAS and was good to excellent for these scales. In particular, the intra-class correlation coefficients for the DAS conviction items was 0.77 (Meyers et al., 2006).

Based on a published factor analysis, we divided the 17 items of the HDRS-17 into two subscales: physical and psychological (Drayer et al., 2005). The psychological subscale includes the items of depressed mood, guilt, suicide, work/interests, retardation, anxiety/psychic, and insight, whereas the remaining items were included in the physical subscale. Because the HRSD hypochondriacal item is rated 4 when somatic delusions are present, we calculated the HDRS physical subscale score while omitting this item. We also assessed the severity of anxiety symptoms with a subscale consisting of the two HDRS-17 anxiety items (anxiety-psychic and anxiety-somatic). We assessed the presence or absence of first-rank Schneiderian symptoms as reflected in the SAPS items assessing voices commenting, voices conversing, thought broadcasting, thought insertion, and thought withdrawal.

Participants were divided into two groups based on the presence or absence of somatic delusion on the SAPS. A somatic delusion was defined as any delusion referring to the body or health. A delusion was rated as primary if the subject was more concerned about this belief than with other endorsed false beliefs. The classification of delusions was made by trained raters, systematically reviewed by one of the study psychiatrists (AJF, AJR, BHM, BSM, EMW), and recorded on the SAPS. The SAPS was used to categorize whether specific delusions were present or absent but not to indicate the severity of these delusions. The demographic and clinical characteristics of these two groups were first compared with univariate analyses using χ^2 and t -tests as applicable, and then a multiple logistic regression was conducted to isolate the independent predictors of somatic delusions. All the variables with univariate p -values < 0.15 were entered in a logistic regression model using backward elimination with the presence or absence of somatic delusion as the dependent variable.

We conducted a secondary analysis using the analytical approach described above, comparing participants with somatic delusions only and those without somatic delusions (i.e., the participants with both somatic and other delusions were excluded).

3. Results

Participants reported a median [range] of 3 [1–13] delusional themes and hallucinations on the SAPS. Fifty-two participants (28%) presented with somatic delusions and 131 (72%) without somatic delusions. Of

the 52 participants with somatic delusions, 15 had only somatic delusions, whereas 37 presented with one or more non-somatic delusions (21 had paranoid delusions, 18 had delusions of guilt or sins, and 31 had other delusions). Table 1 presents the characteristics of the participants with and without somatic delusions.

Participants with somatic delusions were more likely to be aged 60 or older (73% vs. 44%; $\chi^2 = 13.03$, $df = 1$, $p = 0.0003$), to have had a later age of onset of their first depressive episode (mean age (SD): 48.1 (21.5, $n = 46$) vs. 39.3 (21.5, $n = 117$), $t = -3.19$; $df = 177$; $p = 0.002$), and were less likely to have a lifetime diagnosis of an anxiety disorder (30% vs. 49%; $\chi^2 = 5.111$, $df = 1$, $p = 0.02$). There were no differences in sex, race, duration of index episode, percent with previous depressive episodes, or other current or past psychiatric comorbidity between the groups (data not shown).

Participants with somatic delusions had higher total scores on the HDRS-17 due to higher scores on the hypochondrias item (Mean (SD): 3.53 (0.96) vs. 0.99 (1.01); $t = -15.17$, $df = 181$, $p < 0.0001$). They also had higher scores on the HDRS-17 physical subscale, which persisted after omitting the hypochondrias item. No difference was seen on the HDRS-17 psychological subscale. On the BPRS, participants with somatic delusions had higher scores on the somatic concern item and lower scores on the suspiciousness and guilt items. Participants with somatic delusions were less likely to present with first-rank Schneiderian symptoms.

Participants with somatic delusions rated their overall physical health more poorly than those without somatic delusions on the MOS SF-36. Participants with somatic delusions saw a greater number of (non-mental) health professionals and had a greater frequency of contacts during the 3 months prior to study evaluation even though both participant groups had an equivalent objective burden of physical illness as measured by the CIRS-G. The presence of somatic delusions was not associated with differences on other subscales of the CSI involving ancillary medical support services (e.g., physical therapy), ambulatory mental health services, or intensive medical and mental health services (e.g., inpatient treatment) (data not shown).

The final multivariate model ($n = 158$) included only the HDRS physical subscale (OR: 1.18, 95% CI: 1.04–1.34), the self-rated health item on the SF-36 (OR: 1.58, 95% CI: 1.05–2.37), and the presence of a persecutory delusional theme (SAPS item 7; OR: 0.15, 95% CI: 0.07–0.34). In the secondary analysis comparing the 15 participants with somatic delusions only with the 131 without somatic delusions and using the same univariate and

Table 1
Clinical characteristics of patients with psychotic major depression

	With somatic delusions (N=52)		Without somatic delusions (N=131)		Test statistics; <i>df</i> ; <i>p</i> -value
	Mean (SD)	Median [Range]	Mean (SD)	Median [Range]	
MMSE	26.7 (3.5) N=49	27.5 [13–30]	27 (2.8) N=125	28 [17–30]	$t=0.58$; $df=172$; $p=0.56$
HDRS-17					
Total	32.9 (5.1) N=51	32 [22–44]	29.2 (5.2)	29 [20–45]	$t=-4.39$; $df=180$; $p<0.0001$
Physical subscale	16.2 (4.1) N=51	17 [4–22]	12.2 (3.7)	12 [4–22]	$t=-6.34$; $df=180$; $p<0.0001$
Modified physical subscale	12.7 (3.5)	13 [3–18]	11.2 (3.2)	11 [4–20]	$t=-2.71$; $df=181$; $p=0.007$
Psychological subscale	16.7 (2.9)	17 [11–23]	17 (2.8)	17 [10–23]	$t=0.76$; $df=181$; $p=0.45$
Anxiety subscale	5.4 (1.4)	6 [2–8]	5.2 (1.4)	5 [1–8]	$t=-1.09$; $df=181$; $p=0.28$
SAPS (delusions and hallucinations)	3.6 (2.6)	3 [1–13]	3.7 (2.5)	3 [1–12]	$t=0.31$; $df=181$; $p=0.76$
1st Rank Schneiderian symptoms (N, %)	7	14%	37	28%	$\chi^2=4.45$ $df=1$, $p=0.03$
BPRS					
Total	56.8 (10.5) N=51	55 [38–81]	55.2 (10.2) N=130	53.5 [38–89]	$t=-0.93$; $df=179$; $p=0.35$
Somatic concern	6.2 (1.6)	7 [1–7]	2.9 (1.9)	3 [1–6]	$t=-10.73$; $df=181$; $p<0.0001$
Suspiciousness	3.6 (2.5)	3 [1–7]	5.3 (2.2)	7 [1–7]	$t=4.5$; $df=181$; $p<0.0001$
Guilt	4.3 (2.2)	4 [1–7]	5 (2.1)	5 [1–7]	$t=2.29$; $df=181$; $p=0.02$
Anxiety	5.4 (1.7)	5.5 [1–7]	5.7 (1.5)	6 [1–7]	$t=1.11$; $df=181$; $p=0.27$
UKU	14.3 (7.6)	13 [0–35]	12 (7.2)	11 [0–33]	$t=-1.95$; $df=181$; $p=0.06$
SF-36					
MCS	22.2 (8.6) N=45	21.8 [2.9–48.8]	22.5 (9.2) N=117	22.4 [3–52.5]	$t=0.21$; $df=160$; $p=0.84$
PCS	42.3 (11.8) N=45	41.2 [18.7–67]	47.9 (12) N=117	50 [22.1–71.3]	$t=2.7$; $df=160$; $p=0.008$
Self-rated health	3.8 (1.1) N=47	4 [1–5]	3.2 (1.0) N=123	3 [1–5]	$t=-3.31$; $df=168$; $p=0.001$
CIRS-G (modified to exclude psychiatric subscale)					
Total	5.4 (3.7) N=51	5 [0–14]	4.6 (4.3)	4 [0–21]	$t=-1.1$; $df=180$; $p=0.27$
Count	3.4 (2.1)	3 [0–10]	2.8 (2.4)	3 [0–11]	$t=-1.46$; $df=181$; $p=0.15$
CSI					
Medical services count	1.8 (1.6) N=51	1 [0–7]	1.2 (1.1) N=130	1 [0–6]	$t=-2.26$; $df=71.7$; $p=0.03$
Medical visits frequency	4.2 (4.5) N=51	2 [0–16]	2.6 (3.2) N=130	2 [0–17]	$t=-2.21$; $df=71.8$; $p=0.03$

BPRS: Brief Psychiatric Rating Scale; CIRS-G: Cumulative Illness Rating Scale-Geriatric; CSI: Cornell Services Index; HDRS: Hamilton Depression Rating Scale; MMSE: Mini-Mental State Examination; SAPS: Scale for Assessment of Positive Symptoms; SF-36 MCS: Short-form 36-Medical Outcomes Study-Mental Component Summary; SF-36 PCS: Short-form 36-Medical Outcomes Study-Physical Component Summary; UKU: Utvalg for Kliniske Undersøgelser (score reported equals total score less psychiatric symptoms).

multivariate approach described above, the multivariate model ($n=130$) included only the HDRS physical subscale (OR: 1.52, 95% CI: 1.22–1.90) and the total number of delusional themes and hallucinations reported on the SAPS (OR: 0.27, 95% CI: 0.10–0.70).

4. Discussion

Among 183 participants presenting with major depressive disorder with MD-Psy, only three variables – HDRS physical subscale, the self-rated health item on the

SF-36, and the presence of persecutory delusions – differentiated participants with or without somatic delusions. This small number of differences is remarkable given the large number of variables examined. Similarly, only two variables – HDRS physical subscale and the SAPS delusion and hallucination score – differed when comparing participants without any somatic delusions and those with ‘pure’ somatic delusions.

Our findings do not support our a-priori hypotheses. They suggest that, as a group, the presence of somatic delusions does not differentiate a clinically distinct

subgroup of patients with MD-Psy. Both in our primary and secondary analyses, the few variables differentiating participants with and without somatic delusions essentially mirror the classification of participants into these two groups. Namely, participants with somatic delusions report more physical symptoms and worse physical health. The associations with increased age, later age of onset and increased use of medical services apparent in the univariate analyses were not significant after controlling for other factors. It may be that poor self-rated health, which was significant in the multivariate analysis, incorporates these other features of somatic preoccupations among MD-Psy patients with somatic delusions. Participants with ‘pure’ somatic delusion, by definition, did not endorse other delusional themes and hence they have a low SAPS scores.

Somatic preoccupations frequently occur in depressed patients, and the line between delusions and non-delusional somatic worries is not easy to distinguish. With somatic delusions, the patient retains conviction that a somatic preoccupation is realistic, even when faced with conflicting evidence, while a non-delusional patient is able to admit that the concern may be due to a fearful preoccupation rather than resulting from a real physical illness. The thorough and systematic assessment of delusional content applied in this study was used to distinguish anxious ruminations from fixed beliefs. This rigorous assessment is a strength of this study. An additional strength of our study is the inclusion of participants with a wide range of physical illness burden. Limitations of the study include the relatively small number of participants from racial and ethnic minorities, which limits our ability to generalize these findings. Also, while we failed to identify clinical variables distinguishing patients with and without somatic delusions, we did not examine biological data that may distinguish MD-Psy subtypes.

In summary, based on the methods we used, we could not detect meaningful differences between subjects with and without somatic delusions. This suggests that the presence of irrational somatic ideation does not define a distinct clinical subgroup among patients with psychotic depression. Additional studies are needed to replicate this finding and to clarify the dimensions of MD-Psy and its phenomenology.

Role of funding source

Funding for this study or medications were provided by the National Institutes of Health, Eli Lilly and Co., and Pfizer, Inc. as described in the acknowledgments. No sponsor had any further role: in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.

Conflict of interest

Taafoi S. Kamara, Catherine Peasley-Miklus, Moonseong Heo, Eros Papademetriou, and Erin Mathis do not have any potential conflict to acknowledge.

Ellen M. Whyte has received research support from the NIMH, Forest Laboratories, Ortho-McNeil, and Pfizer Inc.

Benoit Mulsant has received research funds or honoraria from NIH, AstraZeneca, Bristol-Myers Squibb Co., Corcept Therapeutics, Eli Lilly and Co., Forest Pharmaceuticals, GlaxoSmithKline, Janssen-Ortho Inc., Lundbeck Inc., and Pfizer Inc.; he directly owns stock (less than \$10,000) in Akzo-Nobel N.V., Alkermes, Inc., AstraZeneca, Biogen Idec, Celsion Corp., Elan Corp., Eli Lilly and Co., Forest Laboratories, and the Immune Response Corporation.

Anthony Rothschild has received research funds or honoraria from Bristol-Myers Squibb Co., Eli Lilly and Co., Cephalon Inc., Cyberonics, Novartis, Wyeth, and Pfizer Inc.; he is a member of the Eli Lilly and Co. Speakers Bureau; he is a consultant for Forest Laboratories, Eli Lilly, Pfizer, and GlaxoSmithKline.

Alastair Flint has received research funds or honoraria from Janssen-Ortho Inc., Organon, and Pfizer Canada Inc.

Barnett S. Meyers has received research funds or honoraria from Forest Laboratories and Pfizer Inc. He has served as a consultant for Eli Lilly and Co., Organon, Pfizer Inc. and Forest Laboratories.

Acknowledgments

This research was supported in part by USPHS grants MH30915, MH48512, MH62446, MH62518, MH62565, MH62624, MH069430, MH067710, and M01RR0056 from the National Institute of Health. Eli Lilly and Co. and Pfizer Inc. provided medications for this study. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute Of Mental Health or the National Institutes of Health.

References

- American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. American Psychiatric Association, Washington, DC.
- Andreasen, N., 1984. The Scale for the Assessment of Positive Symptoms (SAPS). University of Iowa, Iowa City, IA.
- Barsky, A.J., Orav, E.J., Bates, D.W., 2005. Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity. *Arch. Gen. Psychiatry* 62, 903–910.
- Coryell, W., Pfuhl, B., Zimmerman, M., 1984. The clinical and neuroendocrine features of psychotic depression. *J. Nerv. Ment. Dis.* 172 (9), 521–528.
- Drayer, R.A., Mulsant, B.H., Lenze, E.J., Rollman, B.L., Dew, M.A., Kelleher, K., Karp, J.F., Begley, A., Schulberg, H.C., Reynolds 3rd, C.F., 2005. Somatic symptoms of depression in elderly patients with medical comorbidities. *Int. J. Geriatr. Psychiatry* 20 (10), 973–978.
- Folstein, M.F., Folstein, S.E., McHugh, P.R., 1975. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. *J. Psychiatr. Res.* 12, 189–198.
- Hamilton, M., 1960. A rating scale for depression. *J. Neurol. Neurosurg. Psychiatry* 23, 56–62.

- Lingjaerde, O., Ahlfors, U.G., Bech, P., Dencher, S.J., Elgen, K., 1987. The UKU side effect rating scale. *Acta Psychiatr. Scand.* 334 (Supp.), 1–100.
- Meyers, B.S., 1992. Geriatric delusional depression. *Psychiatr. Disord. Late Life* 8 (2), 299–308.
- Meyers, B.S., Greenberg, R., 1986. Late-life delusional depression. *J. Affect. Disord.* 11 (2), 133–137.
- Meyers, B.S., English, J., Gabriele, M., Peasley-Miklus, C., Heo, M., Flint, A., Mulsant, B.H., Rothschild, A., 2006. A delusion assessment scale for psychotic major depression: reliability, validity and utility. *Biol. Psychiatry* 60 (12), 1336–1342.
- Miller, M.D., Paradis, C.F., Houck, P.R., Mazumdar, S., Stack, J.A., Rifai, A.H., Mulsant, B.H., Reynolds 3rd., C.F., 1992. Rating chronic medical illness burden in geropsychiatric research and practice. *Psychiatry Res.* 41, 237–248.
- Overall, J.E., Gorham, D.R., 1962. The brief psychiatric rating scale. *Psychol. Rep.* 10, 799–812.
- Schneider, B., Philipp, M., Muller, M.J., 2001. Psychological predictors of suicide in patients with major depression during a 5-year follow-up. *Eur. Psychiatry* 16, 283–288.
- Sheehan, B., Lall, R., Bass, C., 2005. Does somatization influence quality of life among older primary care patients? *Int. J. Geriatr. Psychiatry* 20, 967–972.
- Sirey, J.A., Meyers, B.S., Teresi, T.A., Bruce, M.L., Ramirez, M., Raue, P.J., Perlick, D.A., Holmes, D., 2005. The Cornell service index as a measure of health service use. *Psychiatr. Serv.* 56, 1564–1569.
- Spitzer, R.L., Endicott, J., 1979. Schedule for Affective Disorders and Schizophrenia — Lifetime Version (SADS). New York State Psychiatric Institute Biometrics Research, New York, NY.
- Spitzer, R.L., Williams, J.B.W., Gibbons, M., 1995. Structured Clinical Interview for Axis I DSM-IV Disorders (SCID). American Psychiatric Association Press Inc., Washington DC.
- Stewart, A.L., Hays, R.D., Ware, J.E., 1988. The MOS short-form general health survey. *Med. Care* 26, 724–735.